APA (7th ed.) Citation

FT, A., JT, G., MB, O., ECW, B., M, J., K, S., . . . MED, C. (2026). Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal for immunotherapy of cancer, 14(7), . https://doi.org/10.1136/jitc-2025-014311

Chicago Style (17th ed.) Citation

FT, Awan, et al. "Pharmacologic Activity, Safety, and Preliminary Efficacy of GEN3009, a CD37-targeting DuoHexaBody, in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma." Journal for Immunotherapy of Cancer 14, no. 7 (2026). https://doi.org/10.1136/jitc-2025-014311.

MLA (9th ed.) Citation

FT, Awan, et al. "Pharmacologic Activity, Safety, and Preliminary Efficacy of GEN3009, a CD37-targeting DuoHexaBody, in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma." Journal for Immunotherapy of Cancer, vol. 14, no. 7, 2026, https://doi.org/10.1136/jitc-2025-014311.